ALKS vs GILD · P/E 14, rev $1.56B vs P/E 18, rev $29.44B
Alkermes Plc (ALKS) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ALKS and GILD stock pages for the full models.
Not investment advice.